- RSV vaccination strongly recommended for Canadians 75 years and
older and particularly those with health conditions that put them
at higher risk of severe RSV disease
- RSV vaccination recommended for consideration by adults aged 60
to 74 years of age in consultation with their health care
provider
MISSISSAUGA, ON, July 16,
2024 /CNW/ - The National Advisory Committee on
Immunization (NACI) has strongly recommended RSV (respiratory
syncytial virus) vaccines, including AREXVY, to reduce the risk of
RSV disease among individuals aged 75 and older, and particularly
those with chronic health conditions that put them at increased
risk of severe RSV disease. NACI also recommends vaccination be
considered by adults aged 60 to 74 years in consultation with their
health care provider. Further, NACI issued a strong recommendation
for publicly funded RSV immunization programs for adults 75 years
and older, especially for those at increased risk of severe RSV
disease, as well as for adults 60 years and older living in nursing
home and other chronic care facilities.i
![National Advisory Committee on Immunization (NACI) recommends RSV vaccines, including AREXVY, for older adult populations (CNW Group/GlaxoSmithKline Inc.) National Advisory Committee on Immunization (NACI) recommends RSV vaccines, including AREXVY, for older adult populations (CNW Group/GlaxoSmithKline Inc.)](https://mma.prnewswire.com/media/2461882/GlaxoSmithKline_Inc__National_Advisory_Committee_on_Immunization.jpg)
RSV is a common, contagious virus that affects the lungs and
respiratory airways. For most people, the virus causes cold-like
symptoms, but for older adults and adults with certain health
conditions it can lead to more serious infection and complications
such as pneumonia, hospitalization and even
death.ii,iii Older adults are at greater risk due
in-part to the natural decline in immune function with
age.iv Underlying medical conditions such as
diabetes, chronic heart and lung disease can be exacerbated by RSV,
leading to severe outcomes.iii According to the most
recent data available, RSV caused an estimated 470,000
hospitalizations and 33,000 deaths in those aged 60 years and above
in high-income countries in 2019.v
Marni Freeman, Country Medical
Director, GSK Canada said: "The NACI recommendation
acknowledges the significant impact that AREXVY can have in
reducing the occurrence and overall impact of respiratory syncytial
virus among over 10 million Canadians aged 60 and
abovevi who are at risk of severe RSV disease. We
look forward to collaborating with public health officials,
healthcare professionals and payers to ensure optimal vaccine
access across the country."
AREXVY was approved in Canada
in August 2023 and is indicated for
the prevention of lower respiratory tract disease (LRTD) caused by
respiratory syncytial virus (RSV) in individuals 60 years of age
and older.vii Approval of AREXVY was based on a
comprehensive Phase III clinical trial program that showed high
vaccine efficacy of 82.6% for prevention of lower respiratory tract
disease caused by RSV in adults ≥60 years of age, and 94.6%
efficacy in older adults with underlying medical conditions.
About RSV in older adults
RSV is a common contagious virus affecting the lungs and
breathing passages.viii For adults 60 and older, data
demonstrate an increased risk for severe RSV infection that can
lead to hospitalization.ix,x Older adults are at
high risk for severe disease due in part to age-related decline in
immunity, and older adults with underlying conditions are at even
greater risk for severe disease.xi, RSV can
exacerbate conditions, including chronic obstructive pulmonary
disease (COPD), asthma, and congestive heart failure and can lead
to severe outcomes, such as pneumonia, hospitalization, and
death. iii
About AREXVY
GSK's RSV older adult vaccine contains a recombinant subunit
prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK's
proprietary AS01E adjuvant. In Canada, AREXVY is indicated for the prevention
of RSV-LRTD in individuals 60 years of age and older and is to be
given intramuscularly as a single dose.iv
The GSK proprietary AS01 adjuvant system contains QS-21 STIMULON
adjuvant licensed from Antigenics Inc, a wholly owned subsidiary of
Agenus Inc.
The Product Monograph, posted at www.ca.gsk.com, should be
consulted for complete administration and safety information.
About GSK
We are a global biopharma company with a purpose to unite
science, technology and talent to get ahead of disease together.
Find out more at www.ca.gsk.com.
__________________________________
i National Advisory Committee on Immunization
(NACI). Statement on the prevention of respiratory syncytial virus
(RSV) disease in older adults. Public Health Agency of Canada, July
2024
|
ii Centers
for Disease Control and Prevention. Symptoms and Care of RSV.
Accessed April 24, 2023. Available at: Symptoms and Care of RSV
(Respiratory Syncytial Virus) | CDC
|
iii Centers
for Disease Control and Prevention. RSV in Older Adults and
Adults with Chronic Medical Conditions. Accessed April 24, 2023.
Available at:
https://www.cdc.gov/rsv/high-risk/older-adults.html
|
iv MedlinePlus. Aging changes in
immunity; https://medlineplus.gov/ency/article/004008.htm (Accessed
April 24, 2023).
|
v Savic
M, Penders Y, Shi T, Branche A, Pirçon J-Y. Respiratory syncytial
virus disease burden in adults aged 60 years and older in
high-income countries: a systematic literature review and
meta-analysis. Influenza Other Respir Viruses 2022 November 11
(Epub ahead of print). [PMID: 36369772]. Accessed 6 December 2022.
Available at: Respiratory syncytial virus disease burden in adults
aged 60 years and older in high–income countries: A systematic
literature review and meta–analysis - Savic - Influenza and Other
Respiratory Viruses - Wiley Online Library
|
vi Statistics Canada. Demographic
estimates by age and sex, provinces and territories. Available at:
Population estimates on July 1st, by age and sex
(statcan.gc.ca)
|
vii Arexvy Product Monograph (2023),
GSK. Available at: www.gsk.ca
|
viii
Canadian Lung Association. Respiratory Syncytial Virus (RSV).
Available at:
https://www.lung.ca/lung-health/lung-disease/respiratory-syncytial-virus-rsv.
|
ix Branche AR, Saiman L, Walsh
EE, et al. Incidence of respiratory syncytial virus
infection among hospitalized adults, 2017-2020. Clin Infect
Dis 2022;74(6):1004-11.
|
x Belongia EA, King JP, Kieke
BA, et al. Clinical features, severity, and incidence
of RSV illness during 12 consecutive seasons in a community cohort
of adults ≥60 years old. Open Forum Infect
Dis 2018;5(12):1-10.
|
xi Weiskopf D, Weinberger B,
Grubeck-Loebenstein B. The aging of the immune system. Transpl Int
2009;22:1041–1050
|
![GSK logo (CNW Group/GlaxoSmithKline Inc.) GSK logo (CNW Group/GlaxoSmithKline Inc.)](https://mma.prnewswire.com/media/2461879/GlaxoSmithKline_Inc__National_Advisory_Committee_on_Immunization.jpg)
SOURCE GlaxoSmithKline Inc.